misc
"タイトル(日本語)","タイトル(英語)","著者(日本語)","著者(英語)","担当区分","概要(日本語)","概要(英語)","出版者・発行元(日本語)","出版者・発行元(英語)","出版年月","誌名(日本語)","誌名(英語)","巻","号","開始ページ","終了ページ","記述言語","査読の有無","招待の有無","掲載種別","国際・国内誌","国際共著","DOI","ISSN","eISSN","URL","URL2","主要な業績かどうか","公開の有無"
"血清アルブミンに存在する超硫黄の解析と創薬応用","血清アルブミンに存在する超硫黄の解析と創薬応用","池田 真由美, 福田 達也, 岩尾 康範, 小田切 優樹, 丸山 徹, 石田 竜弘, 異島 優","Mayumi Ikeda, Tatsuya Fukuta, 岩尾 康範, 小田切 優樹, 丸山 徹, Tatsuhiro Ishida, Yu Ishima","null","null","null","null","null","2024-01","薬学雑誌","Journal of the Pharmaceutical Society of Japan","Vol.144","No.1","51","56","jpn","null","null","introduction_scientific_journal","null","null","10.1248/yakushi.23-00162-3","1347-5231","null","null","null","null","null"
"Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products","Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products","Ibrahim Mohamed, Eslam Mostafa Ramadan Abdelhameed, Nehal Ali Emam Elsadek Emam Elhewan, Sherif Abdallah Emam Emam, Taro Shimizu, Hidenori ANDO, Yu Ishima, Elgarhy Helmy Omar, Sarhan A Hatem, Hussein K Amal, Tatsuhiro Ishida","Ibrahim Mohamed, Eslam Mostafa Ramadan Abdelhameed, Nehal Ali Emam Elsadek Emam Elhewan, Sherif Abdallah Emam Emam, Taro Shimizu, Hidenori ANDO, Yu Ishima, Elgarhy Helmy Omar, Sarhan A Hatem, Hussein K Amal, Tatsuhiro Ishida","null","null","null","null","null","2022-11","Journal of Controlled Release","Journal of Controlled Release","Vol.351","null","215","230","eng","null","null","introduction_scientific_journal","null","null","10.1016/j.jconrel.2022.09.031","0168-3659","null","null","null","null","null"
"The challenge to deliver oxaliplatin (l-OHP) to solid tumors: development of liposomal l-OHP formulations","The challenge to deliver oxaliplatin (l-OHP) to solid tumors: development of liposomal l-OHP formulations","Nana Matsuo, Hidenori ANDO, Yusuke Doi, Taro Shimizu, Yu Ishima, Tatsuhiro Ishida","Nana Matsuo, Hidenori ANDO, Yusuke Doi, Taro Shimizu, Yu Ishima, Tatsuhiro Ishida","null","null","null","null","null","2022-05-01","Chemical & Pharmaceutical Bulletin","Chemical & Pharmaceutical Bulletin","Vol.70","No.5","351","358","eng","null","null","introduction_scientific_journal","null","null","10.1248/cpb.c22-00099","1347-5223","null","null","null","null","null"
"The new delivery strategy of albumin carrier utilizing the interaction with albumin receptors","The new delivery strategy of albumin carrier utilizing the interaction with albumin receptors","Yu Ishima, Toru Maruyama, Masaki Otagiri, G Victor T Chuang, Tatsuhiro Ishida","Yu Ishima, Toru Maruyama, Masaki Otagiri, G Victor T Chuang, Tatsuhiro Ishida","null","null","null","null","null","2022-05-01","Chemical & Pharmaceutical Bulletin","Chemical & Pharmaceutical Bulletin","Vol.70","No.5","330","333","eng","null","null","introduction_scientific_journal","null","null","10.1248/cpb.c21-01024","1347-5223","null","null","null","null","null"
"Drug Delivery System for Refractory Cancer Therapy via an Endogenous Albumin Transport System","Drug Delivery System for Refractory Cancer Therapy via an Endogenous Albumin Transport System","Yu Ishima, Toru Maruyama, Masaki Otagiri, Tatsuhiro Ishida","Yu Ishima, Toru Maruyama, Masaki Otagiri, Tatsuhiro Ishida","null","null","null","null","null","2020-07-01","Chemical & Pharmaceutical Bulletin","Chemical & Pharmaceutical Bulletin","Vol.68","No.7","583","588","eng","null","null","introduction_scientific_journal","null","null","10.1248/cpb.c20-00026","1347-5223","null","null","null","null","null"
"タンパクのPEG修飾によるPEG免疫応答の誘導","タンパクのPEG修飾によるPEG免疫応答の誘導","清水 太郎, 異島 優, 石田 竜弘","Taro Shimizu, Yu Ishima, Tatsuhiro Ishida","null","null","null","null","null","2020-02-01","薬学雑誌","Journal of the Pharmaceutical Society of Japan","Vol.140","No.2","163","169","jpn","null","null","introduction_scientific_journal","null","null","10.1248/yakushi.19-00187-5","1347-5231","null","null","null","null","null"
"内因性アルブミン輸送システムを利用した腫瘍選択的NO供与によるEPR効果の制御","Control of EPR effect by tumor-targeted NO donor via endogenous albumin transport system","異島 優, 丸山 徹, 石田 竜弘, 小田切 優樹","Yu Ishima, 丸山 徹, Tatsuhiro Ishida, 小田切 優樹","null","EPR効果は,高分子抗がん療法の開発の基礎となり得るが,低い血管透過性を有するがん領域では,このEPR効果のみでは十分な送達性が得られない.したがって,一酸化窒素(NO)のような血管調節分子で内因性EPR効果を増強することは極めて有望な戦略である.筆者らは,ヒト血清アルブミン二量体のS―ニトロソ化体(SNO―HSA Dimer)がEPR効果の増強剤であることを検討してきた.ここでは,すでに承認されたPEG化リポソーム・ドキソルビシン(Doxil®)およびアルブミン結合型パクリタキセル・ナノ粒子(Abraxane®)の2種類の高分子抗がん剤を用い,血管透過性が高いC26や血管透過性が低いB16担がんモデル,臨床病態に近いとされているSUIT2ヒト膵臓がん同所性モデルにて得られた結果を中心に報告する.","A unique phenomenon in solid tumors, enhanced permeability and retention(EPR) effect, is very famous for the development of macromolecular anticancer therapy. However, cancers with low vascular permeability posed a challenge for these EPR based therapeutic systems. An intrinsic vascular modulator such as nitric oxide(NO) could augment the intrinsic EPR effect. We have demonstrated that S-nitrosated human serum albumin dimer(SNO-HSA Dimer) becomes an enhancer of the EPR effect in various tumor-bearing mice models. Here, we summarized the enhanced effect of SNO-HSA Dimer on the anticancer effect of two types of macromolecular anticancer drugs, namely PEGylated liposomal doxorubicin(Doxil®) and albumin bound paclitaxel nanoparticle(Abraxane®). In C26-bearing mice with highly permeable vasculature, SNO-HSA Dimer could increase tumor accumulation of these anticancer drugs and thereby their anticancer effects. Interestingly, the tumor accumulation of Doxil® in B16-bearing mice, which are characterized by a low permeable vasculature, increased more 6-fold in the presence of SNO-HSA Dimer, and the improved accumulation of Doxil® led to increased survival and decreased tumor volume. On the other hand, SNO-HSA Dimer also augmented the tumor growth inhibition of Abraxane® in low vascular permeability B16-bearing mice. Furthermore, Abraxane® combined with SNO-HSA Dimer showed higher antitumor activity and improved survival rate of SUIT2 human pancreatic cancer orthotopic model. We also showed that the administration of SNO-HSA Dimer had no effect on blood pressure, heart rate and biochemical parameters, suggesting that SNO-HSA Dimer alone is very safe. Accordingly, we conclude that SNO-HSA Dimer is promising for regulating the EPR effect and enhanced therapeutic effects of many macromolecular anticancer drugs.","null","null","2018-03-25","Drug Delivery System","Drug Delivery System","Vol.33","No.2","130","138","jpn","null","null","introduction_scientific_journal","null","null","10.2745/dds.33.130","0913-5006","null","http://id.ndl.go.jp/bib/028929708","null","null","null"
"Accelerated blood clearance (ABC) 現象における動物種差","Accelerated blood clearance (ABC) 現象における動物種差","清水 太郎, 異島 優, 石田 竜弘","Taro Shimizu, Yu Ishima, Tatsuhiro Ishida","null","null","null","null","null","2017-11","Drug Delivery System","Drug Delivery System","Vol.32","No.5","396","401","jpn","null","null","introduction_scientific_journal","null","null","10.2745/dds.32.396","1881-2732","null","null","null","null","null"
"ナノ粒子に対する補体活性化の功罪","ナノ粒子に対する補体活性化の功罪","清水 太郎, 異島 優, 石田 竜弘","Taro Shimizu, Yu Ishima, Tatsuhiro Ishida","null","null","null","null","null","2017-08","Drug Delivery System","Drug Delivery System","Vol.32","No.3","199","207","jpn","null","null","introduction_scientific_journal","null","null","10.2745/dds.32.199","1881-2732","null","null","null","null","null"
"Poly-S-Nitrosated Albumin as a Safe and Effective Multifunctional Antitumor Agent: Characterization, Biochemistry and Possible Future Therapeutic Applications","Poly-S-Nitrosated Albumin as a Safe and Effective Multifunctional Antitumor Agent: Characterization, Biochemistry and Possible Future Therapeutic Applications","Yu Ishima, U Kragh-Hansen, T Maruyama, M Otagiri","Yu Ishima, U Kragh-Hansen, T Maruyama, M Otagiri","null","Nitric oxide (NO) is a ubiquitous molecule involved in multiple cellular functions. Inappropriate production of NO may lead to disease states. To date, pharmacologically active compounds that release NO within the body, such as organic nitrates, have been used as therapeutic agents, but their efficacy is significantly limited by unwanted side effects. Therefore, novel NO donors with better pharmacological and pharmacokinetic properties are highly desirable. The S-nitrosothiol fraction in plasma is largely composed of endogenous S-nitrosated human serum albumin (Mono-SNO-HSA), and that is why we are testing whether this albumin form can be therapeutically useful. Recently, we developed SNO-HSA analogs such as SNO-HSA with many conjugated SNO groups (Poly-SNO-HSA) which were prepared using chemical modification. Unexpectedly, we found striking inverse effects between Poly-SNO-HSA and Mono-SNO-HSA. Despite the fact that Mono-SNO-HSA inhibits apoptosis, Poly-SNO-HSA possesses very strong proapoptotic effects against tumor cells. Furthermore, Poly-SNO-HSA can reduce or perhaps completely eliminate the multidrug resistance often developed by cancer cells. In this review, we forward the possibility that Poly-SNO-HSA can be used as a safe and effective multifunctional antitumor agent.","Nitric oxide (NO) is a ubiquitous molecule involved in multiple cellular functions. Inappropriate production of NO may lead to disease states. To date, pharmacologically active compounds that release NO within the body, such as organic nitrates, have been used as therapeutic agents, but their efficacy is significantly limited by unwanted side effects. Therefore, novel NO donors with better pharmacological and pharmacokinetic properties are highly desirable. The S-nitrosothiol fraction in plasma is largely composed of endogenous S-nitrosated human serum albumin (Mono-SNO-HSA), and that is why we are testing whether this albumin form can be therapeutically useful. Recently, we developed SNO-HSA analogs such as SNO-HSA with many conjugated SNO groups (Poly-SNO-HSA) which were prepared using chemical modification. Unexpectedly, we found striking inverse effects between Poly-SNO-HSA and Mono-SNO-HSA. Despite the fact that Mono-SNO-HSA inhibits apoptosis, Poly-SNO-HSA possesses very strong proapoptotic effects against tumor cells. Furthermore, Poly-SNO-HSA can reduce or perhaps completely eliminate the multidrug resistance often developed by cancer cells. In this review, we forward the possibility that Poly-SNO-HSA can be used as a safe and effective multifunctional antitumor agent.","null","null","2013-12-30","BioMed Research International","BioMed Research International","Vol.2013","null","353892","353892","eng","null","null","introduction_scientific_journal","null","null","10.1155/2013/353892","2314-6141","null","null","null","null","null"